Segments of Business and Geographic Areas (Tables)

12 Months Ended

Jan. 03, 2021

Segment Reporting [Abstract]

Schedule of Sales by Segment of Business

	Sales to Customers				% Change
(Dollars in Millions)	2020		2019	2018	’20 vs. ’19		’19 vs. ’18
Consumer Health)(1)
OTC
U.S.	$	2,460	2,010	1,850	22.4	%	8.6
International	2,364		2,434	2,484	(2.9)		(2.0)
Worldwide	4,824		4,444	4,334	8.5		2.5
Skin Health/Beauty(2)
U.S.	2,350		2,392	2,403	(1.7)		(0.4)
International	2,100		2,201	1,979	(4.6)		11.2
Worldwide	4,450		4,593	4,382	(3.1)		4.8
Oral Care
U.S.	683		621	637	9.9		(2.5)
International	958		906	918	5.7		(1.2)
Worldwide	1,641		1,528	1,555	7.4		(1.7)
Baby Care
U.S.	376		362	422	3.7		(14.2)
International	1,141		1,313	1,436	(13.1)		(8.6)
Worldwide	1,517		1,675	1,858	(9.4)		(9.9)
Women's Health
U.S.	13		12	13	8.2		(5.5)
International	888		974	1,036	(8.8)		(6.0)
Worldwide	901		986	1,049	(8.6)		(6.0)
Wound Care/Other
U.S.	480		441	436	8.9		1.2
International	240		230	239	4.1		(3.9)
Worldwide	720		671	675	7.2		(0.6)
TOTAL CONSUMER HEALTH
U.S.	6,362		5,839	5,761	9.0		1.4
International	7,691		8,059	8,092	(4.6)		(0.4)
Worldwide	14,053		13,898	13,853	1.1		0.3
(1)Previously referred to as Consumer (2)Previously referred to as Beauty

PHARMACEUTICAL
Immunology
U.S.	10,175	9,641	9,073	5.5	6.3
International	4,880	4,309	4,047	13.2	6.5
Worldwide	15,055	13,950	13,120	7.9	6.3
REMICADE®
U.S.	2,508	3,079	3,664	(18.5)	(16.0)
U.S. Exports	346	294	436	18.0	(32.7)
International	893	1,007	1,226	(11.4)	(17.8)
Worldwide	3,747	4,380	5,326	(14.4)	(17.8)
SIMPONI / SIMPONI ARIA®
U.S.	1,155	1,159	1,051	(0.3)	10.2
International	1,088	1,029	1,033	5.8	(0.4)
Worldwide	2,243	2,188	2,084	2.6	5.0
STELARA®
U.S.	5,240	4,346	3,469	20.6	25.3
International	2,467	2,015	1,687	22.4	19.4
Worldwide	7,707	6,361	5,156	21.1	23.4
TREMFYA®
U.S.	926	764	453	21.3	68.5
International	421	248	91	69.9	**
Worldwide	1,347	1,012	544	33.2	85.9
OTHER IMMUNOLOGY
U.S.	—	—	—	—	—
International	11	10	10	6.4	4.5
Worldwide	11	10	10	6.4	4.5
Infectious Diseases
U.S.	1,735	1,597	1,378	8.6	15.9
International	1,839	1,815	1,926	1.3	(5.7)
Worldwide	3,574	3,413	3,304	4.7	3.3
EDURANT® / rilpivirine
U.S.	44	50	58	(11.2)	(13.7)
International	920	812	758	13.3	7.1
Worldwide	964	861	816	11.9	5.6
PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA®
U.S.	1,587	1,422	1,169	11.6	21.6
International	597	689	786	(13.4)	(12.3)
Worldwide	2,184	2,110	1,955	3.5	8.0
OTHER INFECTIOUS DISEASES
U.S.	104	126	151	(17.6)	(16.5)
International	323	315	382	2.6	(17.6)
Worldwide	427	441	533	(3.2)	(17.3)

Neuroscience
U.S.	3,091	2,919	2,574	5.9	13.4
International	3,457	3,409	3,503	1.4	(2.7)
Worldwide	6,548	6,328	6,077	3.5	4.1
CONCERTA® / methylphenidate
U.S.	183	233	229	(21.4)	1.7
International	439	463	434	(5.1)	6.6
Worldwide	622	696	663	(10.6)	4.9
INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA®
U.S.	2,314	2,107	1,791	9.8	17.6
International	1,339	1,224	1,137	9.4	7.7
Worldwide	3,653	3,330	2,928	9.7	13.7
RISPERDAL CONSTA®
U.S.	296	314	315	(5.9)	(0.3)
International	346	374	422	(7.5)	(11.4)
Worldwide	642	688	737	(6.8)	(6.7)
OTHER NEUROSCIENCE
U.S.	298	266	239	12.4	11.4
International	1,334	1,349	1,510	(1.1)	(10.7)
Worldwide	1,632	1,614	1,749	1.1	(7.7)
Oncology
U.S.	5,092	4,299	4,331	18.5	(0.7)
International	7,275	6,393	5,513	13.8	16.0
Worldwide	12,367	10,692	9,844	15.7	8.6
DARZALEX®
U.S.	2,232	1,567	1,203	42.4	30.3
International	1,958	1,430	822	36.9	73.9
Worldwide	4,190	2,998	2,025	39.8	48.0
ERLEADA®
U.S.	583	297	124	96.1	**
International	176	35	—	* *	**
Worldwide	760	332	124	* *	**
IMBRUVICA®
U.S.	1,821	1,555	1,129	17.1	37.7
International	2,307	1,856	1,486	24.3	24.9
Worldwide	4,128	3,411	2,615	21.0	30.4
VELCADE®
U.S.	—	—	—	—	—
International	408	751	1,116	(45.7)	(32.7)
Worldwide	408	751	1,116	(45.7)	(32.7)
ZYTIGA® /abiraterone acetate
U.S.	373	810	1,771	(54.0)	(54.3)
International	2,097	1,985	1,727	5.6	15.0
Worldwide	2,470	2,795	3,498	(11.6)	(20.1)

OTHER ONCOLOGY
U.S.	83	70	104	19.2	(32.7)
International	330	336	362	(1.9)	(7.2)
Worldwide	413	407	466	1.7	(12.7)
Pulmonary Hypertension
U.S.	2,133	1,684	1,651	26.6	2.0
International	1,015	939	922	8.2	1.9
Worldwide	3,148	2,623	2,573	20.0	1.9
OPSUMIT®
U.S.	1,008	766	700	31.7	9.4
International	631	562	515	12.3	9.0
Worldwide	1,639	1,327	1,215	23.5	9.2
UPTRAVI®
U.S.	955	714	598	33.8	19.3
International	138	105	65	30.9	62.4
Worldwide	1,093	819	663	33.5	23.5
OTHER
U.S.	169	205	353	(17.6)	(41.9)
International	247	272	342	(9.2)	(20.5)
Worldwide	416	476	695	(12.8)	(31.5)
Cardiovascular / Metabolism / Other
U.S.	3,509	3,734	4,279	(6.0)	(12.7)
International	1,369	1,458	1,537	(6.1)	(5.2)
Worldwide	4,878	5,192	5,816	(6.0)	(10.7)
XARELTO®
U.S.	2,345	2,313	2,477	1.4	(6.6)
International	—	—	—	—	—
Worldwide	2,345	2,313	2,477	1.4	(6.6)
INVOKANA® / INVOKAMET®
U.S.	564	536	711	5.2	(24.6)
International	231	199	170	16.3	17.3
Worldwide	795	735	881	8.2	(16.5)
PROCRIT® / EPREX®
U.S.	277	505	674	(45.1)	(25.1)
International	274	285	314	(3.8)	(9.2)
Worldwide	552	790	988	(30.2)	(20.0)
OTHER
U.S.	323	380	417	(15.1)	(9.1)
International	864	974	1,053	(11.3)	(7.6)
Worldwide	1,186	1,353	1,470	(12.4)	(8.0)
TOTAL PHARMACEUTICAL
U.S.	25,735	23,874	23,286	7.8	2.5
International	19,837	18,324	17,448	8.3	5.0
Worldwide	45,572	42,198	40,734	8.0	3.6

MEDICAL DEVICES
Diabetes Care
U.S.	—	—	371	—	**
International	—	—	638	—	**
Worldwide	—	—	1,009	—	**
Interventional Solutions
U.S.	1,452	1,443	1,283	0.6	12.5
International	1,594	1,554	1,363	2.6	14.0
Worldwide	3,046	2,997	2,646	1.6	13.3
Orthopaedics
U.S.	4,779	5,319	5,281	(10.2)	0.7
International	2,984	3,520	3,604	(15.2)	(2.3)
Worldwide	7,763	8,839	8,885	(12.2)	(0.5)
HIPS
U.S.	793	863	841	(8.2)	2.6
International	487	575	577	(15.3)	(0.3)
Worldwide	1,280	1,438	1,418	(11.0)	1.4
KNEES
U.S.	743	889	911	(16.4)	(2.4)
International	427	591	591	(27.8)	0.0
Worldwide	1,170	1,480	1,502	(21.0)	(1.4)
TRAUMA
U.S.	1,648	1,652	1,599	(0.2)	3.3
International	966	1,068	1,100	(9.6)	(2.9)
Worldwide	2,614	2,720	2,699	(3.9)	0.8
SPINE, SPORTS & OTHER(3)
U.S.	1,595	1,915	1,930	(16.7)	(0.8)
International	1,104	1,286	1,336	(14.1)	(3.8)
Worldwide	2,699	3,201	3,266	(15.7)	(2.0)
Surgery
U.S.	3,249	3,828	4,125	(15.1)	(7.2)
International	4,983	5,673	5,776	(12.2)	(1.8)
Worldwide	8,232	9,501	9,901	(13.4)	(4.0)
ADVANCED
U.S.	1,535	1,637	1,657	(6.2)	(1.2)
International	2,304	2,458	2,345	(6.2)	4.8
Worldwide	3,839	4,095	4,002	(6.2)	2.3
GENERAL
U.S.	1,714	2,192	2,468	(21.8)	(11.2)
International	2,679	3,215	3,431	(16.7)	(6.3)
Worldwide	4,392	5,406	5,899	(18.8)	(8.4)
Vision
U.S.	1,557	1,794	1,777	(13.2)	0.9
International	2,362	2,830	2,776	(16.5)	2.0
Worldwide	3,919	4,624	4,553	(15.2)	1.6

CONTACT LENSES / OTHER
U.S.	1,213		1,304	1,237	(7.0)		5.4
International	1,781		2,088	2,065	(14.7)		1.1
Worldwide	2,994		3,392	3,302	(11.7)		2.7
SURGICAL
U.S.	344		490	540	(29.7)		(9.4)
International	581		742	711	(21.7)		4.4
Worldwide	925		1,232	1,251	(24.9)		(1.6)
TOTAL MEDICAL DEVICES
U.S.	11,036		12,384	12,837	(10.9)		(3.5)
International	11,923		13,579	14,157	(12.2)		(4.1)
Worldwide	22,959		25,963	26,994	(11.6)		(3.8)
WORLDWIDE
U.S.	43,133		42,097	41,884	2.5		0.5
International	39,451		39,962	39,697	(1.3)		0.7
Worldwide	$	82,584	82,059	81,581	0.6	%	0.6

(3)Previously referred to as Spine & Other

*Certain prior year amounts have been reclassified to conform to current year presentation

**Percentage greater than 100% or not meaningful

Schedule of Segment Reporting Information

	Income (Loss) Before Tax				Identifiable Assets
(Dollars in Millions)	2020 (3)		2019 (4)	2018 (5)	2020		2019
Consumer Health	$	(1,064)	2,061	2,320	$	27,355	26,618
Pharmaceutical	15,462		8,816	12,568	66,158		56,292
Medical Devices	3,044		7,286	4,397	49,578		49,462
Total	17,442		18,163	19,285	143,091		132,372
Less: Expense not allocated to segments (1)	945		835	1,286
General corporate (2)					31,803		25,356
Worldwide total	$	16,497	17,328	17,999	$	174,894	157,728

	Additions to Property, Plant & Equipment				Depreciation and Amortization
(Dollars in Millions)	2020		2019	2018	2020		2019	2018
Consumer Health	$	248	328	438	$	785	765	688
Pharmaceutical	863		950	1,012	4,006		3,910	3,802
Medical Devices	1,980		1,912	1,843	2,140		2,014	2,103
Segments total	3,091		3,190	3,293	6,931		6,689	6,593
General corporate	256		308	377	300		320	336
Worldwide total	$	3,347	3,498	3,670	$	7,231	7,009	6,929

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas

	Sales to Customers				Long-Lived Assets (6)
(Dollars in Millions)	2020		2019	2018	2020		2019
United States	$	43,133	42,097	41,884	$	49,951	41,528
Europe	18,980		18,466	18,753	49,363		48,015
Western Hemisphere excluding U.S.	5,335		5,941	6,113	2,734		2,862
Asia-Pacific, Africa	15,136		15,555	14,831	5,484		5,486
Segments total	82,584		82,059	81,581	107,532		97,891
General corporate					1,029		1,049
Other non long-lived assets					66,333		58,788
Worldwide total	$	82,584	82,059	81,581	$	174,894	157,728

See Note 1 for a description of the segments in which the Company operates.

Export sales are not significant. In fiscal year 2020, the Company utilized three wholesalers distributing products for all three segments that represented approximately 16.0%, 12.0% and 12.0% of the total consolidated revenues. In fiscal year 2019, the Company had three wholesalers distributing products for all three segments that represented approximately 15.0%, 12.0% and 11.0% of the total consolidated revenues. In fiscal year 2018, the Company had three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0%, and 11.0% of the total consolidated revenues.

(1)Amounts not allocated to segments include interest (income) expense and general corporate (income) expense.

(2)General corporate includes cash, cash equivalents and marketable securities.

(3)Consumer Health includes:

•Litigation expense of $3.9 billion, primarily talc related reserves and certain settlements.

Pharmaceutical includes:

•Litigation expense of $0.8 billion, primarily related to the agreement in principle to settle opioid litigation

•An unrealized gain on securities of $0.5 billion

•A restructuring related charge of $0.1 billion

Medical Devices includes:

•A contingent consideration reversal of $1.1 billion related to the timing of certain developmental milestones associated with the Auris Health acquisition.

•Litigation expense of $0.3 billion

•A restructuring related charge of $0.3 billion

•An in-process research and development expense of $0.2 billion

•A Medical Device Regulation charge of $0.1 billion

(4) Consumer Health includes:

•A gain of $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO

•Litigation expense of $0.4 billion

•A restructuring related charge of $0.1 billion

Pharmaceutical includes:

•Litigation expense of $4.3 billion of which $4.0 billion is related to the agreement in principle to settle opioid litigation

•An in-process research and development expense of $0.9 billion related to the Alios asset

•A research and development expense of $0.3 billion for an upfront payment related to argenx

•An unrealized gain on securities of $0.6 billion

•Actelion acquisition and integration related costs of $0.2 billion

•A restructuring charge of $0.1 billion

Medical Devices includes:

•A gain of $2.0 billion from the divestiture of the ASP business

•A restructuring related charge of $0.4 billion

•Litigation expense of $0.4 billion

•Auris Health acquisition and integration related costs of $0.1 billion

(5) Consumer Health includes:

•A gain of $0.3 billion from the divestiture of NIZORAL®

•Litigation expense of $0.3 billion

Pharmaceutical includes:

•An in-process research and development charge of $1.1 billion related to the Alios and XO1 assets and the corresponding XO1 contingent liability reversal of $0.2 billion

•Actelion acquisition and integration related costs of $0.2 billion

•An unrealized loss on securities of $0.2 billion

•A gain of $0.2 billion from the divestiture of certain non-strategic Pharmaceutical products

Medical Devices includes:

•Litigation expense of $1.7 billion

•A restructuring related charge of $0.6 billion

•AMO acquisition and integration related costs of $0.1 billion

•A gain of $0.5 billion from the divestiture of the LifeScan business

(6) Long-lived assets include property, plant and equipment, net for fiscal years 2020, and 2019 of $18,766 and $17,658, respectively, and intangible assets and goodwill, net for fiscal years 2020 and 2019 of $89,795 and $81,282, respectively.